XF-73, Destiny Pharma’s new antimicrobial, is in Phase IIb for the prevention of staphylococcal surgical infections and seems to be in the right place at the right time. Recent press reports suggest that in most developed markets, cutting screening for nasal staphylococcal carriage before surgery was associated with patient deaths. Another recent paper highlighted the mortality benefit of nasal decolonisation.
25 Feb 2019
Destiny Pharma - Prevention is commercially cost effective
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Destiny Pharma - Prevention is commercially cost effective
Destiny Pharma Plc (DEST:LON) | 21.2 0.4 10.4% | Mkt Cap: 20.3m
- Published:
25 Feb 2019 -
Author:
Dr Andy Smith -
Pages:
3
XF-73, Destiny Pharma’s new antimicrobial, is in Phase IIb for the prevention of staphylococcal surgical infections and seems to be in the right place at the right time. Recent press reports suggest that in most developed markets, cutting screening for nasal staphylococcal carriage before surgery was associated with patient deaths. Another recent paper highlighted the mortality benefit of nasal decolonisation.